share_log

Needham Reiterates Buy on BioCryst Pharma, Maintains $12 Price Target

Benzinga ·  Jan 8 05:52

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $12 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment